Correlation Between Dermata Therapeutics and United Therapeutics
Can any of the company-specific risk be diversified away by investing in both Dermata Therapeutics and United Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Dermata Therapeutics and United Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Dermata Therapeutics and United Therapeutics, you can compare the effects of market volatilities on Dermata Therapeutics and United Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Dermata Therapeutics with a short position of United Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Dermata Therapeutics and United Therapeutics.
Diversification Opportunities for Dermata Therapeutics and United Therapeutics
-0.47 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Dermata and United is -0.47. Overlapping area represents the amount of risk that can be diversified away by holding Dermata Therapeutics and United Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on United Therapeutics and Dermata Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Dermata Therapeutics are associated (or correlated) with United Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of United Therapeutics has no effect on the direction of Dermata Therapeutics i.e., Dermata Therapeutics and United Therapeutics go up and down completely randomly.
Pair Corralation between Dermata Therapeutics and United Therapeutics
Given the investment horizon of 90 days Dermata Therapeutics is expected to under-perform the United Therapeutics. In addition to that, Dermata Therapeutics is 5.01 times more volatile than United Therapeutics. It trades about 0.0 of its total potential returns per unit of risk. United Therapeutics is currently generating about 0.05 per unit of volatility. If you would invest 35,337 in United Therapeutics on September 4, 2024 and sell it today you would earn a total of 1,542 from holding United Therapeutics or generate 4.36% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Against |
Strength | Very Weak |
Accuracy | 100.0% |
Values | Daily Returns |
Dermata Therapeutics vs. United Therapeutics
Performance |
Timeline |
Dermata Therapeutics |
United Therapeutics |
Dermata Therapeutics and United Therapeutics Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Dermata Therapeutics and United Therapeutics
The main advantage of trading using opposite Dermata Therapeutics and United Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Dermata Therapeutics position performs unexpectedly, United Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in United Therapeutics will offset losses from the drop in United Therapeutics' long position.Dermata Therapeutics vs. Candel Therapeutics | Dermata Therapeutics vs. Cingulate Warrants | Dermata Therapeutics vs. Unicycive Therapeutics | Dermata Therapeutics vs. Cardio Diagnostics Holdings |
United Therapeutics vs. Incyte | United Therapeutics vs. Alnylam Pharmaceuticals | United Therapeutics vs. Ultragenyx | United Therapeutics vs. Apellis Pharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Other Complementary Tools
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
CEOs Directory Screen CEOs from public companies around the world | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |